gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma (Q34188859)

31 July 2017

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma (English)

1 reference

31 July 2017

0 references

0 references

1 reference

23

Steven A Rosenberg

1 reference

31 July 2017

20

Howard Kaufman

1 reference

31 July 2017

21

Francesco M Marincola

1 reference

31 July 2017

26

Patrick Hwu

1 reference

31 July 2017

Douglas J Schwartzentruber

1

1 reference

31 July 2017

David H Lawson

2

1 reference

31 July 2017

Jon M Richards

3

1 reference

31 July 2017

Robert M Conry

4

1 reference

31 July 2017

Donald M Miller

5

1 reference

31 July 2017

Jonathan Treisman

6

1 reference

31 July 2017

Fawaz Gailani

7

1 reference

31 July 2017

Lee Riley

8

1 reference

31 July 2017

Kevin Conlon

9

1 reference

31 July 2017

Barbara Pockaj

10

1 reference

31 July 2017

Kari L Kendra

11

1 reference

31 July 2017

Richard L White

12

1 reference

31 July 2017

Rene Gonzalez

13

1 reference

31 July 2017

Timothy M Kuzel

14

1 reference

31 July 2017

Brendan Curti

15

1 reference

31 July 2017

Phillip D Leming

16

1 reference

31 July 2017

Eric D Whitman

17

1 reference

31 July 2017

Jai Balkissoon

18

1 reference

31 July 2017

Douglas S Reintgen

19

1 reference

31 July 2017

Maria J Merino

22

1 reference

31 July 2017

Peter Choyke

24

1 reference

31 July 2017

Don Vena

25

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

The New England Journal of Medicine

31 July 2017

1 reference

31 July 2017

364

1 reference

31 July 2017

2119-2127

1 reference

31 July 2017

22

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Less yin, more yang: confronting the barriers to cancer immunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Checkpoint blockade in cancer immunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

The future of interleukin-2: enhancing therapeutic anticancer vaccines

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517182

28 October 2018

Identifiers

DOI

10.1056/NEJMOA1012863

1 reference

31 July 2017

1 reference

31 July 2017

1 reference